GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (STU:296) » Definitions » Interest Expense (Positive)

CytoDyn (STU:296) Interest Expense (Positive)


View and export this data going back to 2016. Start your Free Trial

What is CytoDyn Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.


CytoDyn Business Description

Industry
Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.